228 related articles for article (PubMed ID: 21795072)
21. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S
J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687
[TBL] [Abstract][Full Text] [Related]
22. HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3).
Bongiovanni L; Arena V; Vecchio FM; Racioppi M; Bassi P; Pierconti F
Arch Ital Urol Androl; 2013 Jun; 85(2):73-7. PubMed ID: 23820653
[TBL] [Abstract][Full Text] [Related]
23. Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer.
Inamoto T; Czerniak BA; Dinney CP; Kamat AM
Cancer; 2010 Jan; 116(2):340-6. PubMed ID: 19908257
[TBL] [Abstract][Full Text] [Related]
24. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers.
Migaldi M; Sgambato A; Garagnani L; Ardito R; Ferrari P; De Gaetani C; Cittadini A; Trentini GP
Clin Cancer Res; 2000 Aug; 6(8):3131-8. PubMed ID: 10955794
[TBL] [Abstract][Full Text] [Related]
25. Utility of SAM68 in the progression and prognosis for bladder cancer.
Zhang Z; Yu C; Li Y; Jiang L; Zhou F
BMC Cancer; 2015 May; 15():364. PubMed ID: 25944080
[TBL] [Abstract][Full Text] [Related]
26. Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2.
Vischioni B; Giaccone G; Span SW; Kruyt FA; Rodriguez JA
Exp Cell Res; 2004 Aug; 298(2):535-48. PubMed ID: 15265700
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of Bcl-2 and Bax tumor cell expression in patients with non muscle-invasive bladder cancer receiving bacillus Calmette-Guerin immunotherapy.
Ajili F; Kaabi B; Darouiche A; Tounsi H; Kourda N; Chebil M; Manai M; Boubaker S
Ultrastruct Pathol; 2012 Feb; 36(1):31-9. PubMed ID: 22292735
[TBL] [Abstract][Full Text] [Related]
28. Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer.
Kamai T; Takagi K; Asami H; Ito Y; Oshima H; Yoshida KI
Br J Cancer; 2001 May; 84(9):1242-51. PubMed ID: 11336477
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of maspin and Ki-67 expression in transurethral resection specimens in patients with T1 bladder cancer.
Acikalin D; Oner U; Can C; Acikalin MF; Colak E
Tumori; 2012; 98(3):344-50. PubMed ID: 22825520
[TBL] [Abstract][Full Text] [Related]
30. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
Klatte T; Seligson DB; Rao JY; Yu H; de Martino M; Kawaoka K; Wong SG; Belldegrun AS; Pantuck AJ
Cancer; 2009 Apr; 115(7):1448-58. PubMed ID: 19195047
[TBL] [Abstract][Full Text] [Related]
31. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
33. Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Dohn LH; Illemann M; Høyer-Hansen G; Christensen IJ; Hostmark J; Litlekalsoy J; von der Maase H; Pappot H; Laerum OD
Urol Oncol; 2015 Apr; 33(4):165.e15-24. PubMed ID: 25575713
[TBL] [Abstract][Full Text] [Related]
34. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
35. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder.
Wang H; Albadine R; Magheli A; Guzzo TJ; Ball MW; Hinz S; Schoenberg MP; Netto GJ; Gonzalgo ML
Urol Oncol; 2012; 30(4):428-33. PubMed ID: 21396836
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer.
Yoshii H; Ito K; Asano T; Horiguchi A; Hayakawa M; Asano T
Oncol Rep; 2013 Sep; 30(3):1073-80. PubMed ID: 23817592
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
March-Villalba JA; Ramos-Soler D; Soriano-Sarrió P; Hervás-Marín D; Martínez-García L; Martínez-Jabaloyas JM
Urol Oncol; 2019 Feb; 37(2):158-165. PubMed ID: 30446453
[TBL] [Abstract][Full Text] [Related]
38. High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma.
Wu XR; Sha JJ; Liu DM; Chen YH; Yang GL; Zhang J; Chen YY; Bo JJ; Huang YR
Eur J Surg Oncol; 2013 Jan; 39(1):100-6. PubMed ID: 23102595
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non-muscle-invasive bladder cancer.
Kim JH; Park J
Hum Pathol; 2014 Sep; 45(9):1830-8. PubMed ID: 24957789
[TBL] [Abstract][Full Text] [Related]
40. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
